Enhanced neurobiological biomarker differentiation for attention-deficit/hyperactivity disorder through a risk-informed design
Duarte I, Hoffmann M, Salum G, Leffa D, Belangero S, Santoro M, Ota V, Ito L, Pan P, Farhat L, Murray A, Miguel E, Kieling C, Rohde L, Caye A. Enhanced neurobiological biomarker differentiation for attention-deficit/hyperactivity disorder through a risk-informed design. European Child & Adolescent Psychiatry 2024, 1-11. PMID: 39625683, DOI: 10.1007/s00787-024-02622-4.Peer-Reviewed Original ResearchNeurobiological measuresADHD polygenic scoresBrazilian High-Risk CohortAttention-deficit/hyperactivity disorderPoorer executive functionPolygenic scoresADHD symptomsExecutive functionHigh-risk subgroupsAttention-deficit/hyperactivitySubcortical volumesHigh-risk cohortMental disordersADHD casesEffect sizeADHDMental conditionDifferential riskClinical practiceRisk cohortBiomarkers to clinical practiceLow-risk groupCalculated riskParticipantsAdolescents